Calendario›REGN›Vonsetamig

Vonsetamig

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

Ensayo de REGENERON PHARMACEUTICALS, INC. en Lupus Nephritis (LN) (del registro, en inglés).

Fase

Fase 1

Estado

Reclutando pacientes

Participantes

90

previstos

Centros

19

Fin del objetivo primario

sep 2029

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en dic 2025.

Qué mide

Occurrence of Dose Limiting Toxicities (DLT) (del registro, en inglés) (hasta 56 dias)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN). The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up. This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06975787), actualizada en sep 2026.